Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY19 results · Jan–Mar 2019
Natco Pharma reported revenue from operations of ₹455.70 crore and net profit of ₹120.40 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 455.70 | — | — | 556.70 | −18.1% |
| Other income | 31.00 | — | — | 23.30 | +33.0% |
| Total income | 486.70 | — | — | 580.00 | −16.1% |
| Profit before tax | 152.40 | — | — | 204.70 | −25.5% |
| Net profit for the period | 120.40 | — | — | 159.30 | −24.4% |
| Attributable to shareholders of the company | 120.80 | — | — | 159.50 | −24.3% |
| EPS, basic (₹) | 6.59 | — | — | 8.65 | −23.8% |
| Net margin (%) | 26.4 | — | 28.6 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 416.30 | — | — | 531.90 | −21.7% |
| Other income | 30.70 | — | — | 23.70 | +29.5% |
| Total income | 447.00 | — | — | 555.60 | −19.5% |
| Profit before tax | 154.40 | — | — | 206.40 | −25.2% |
| Net profit for the period | 123.40 | — | — | 162.00 | −23.8% |
| EPS, basic (₹) | 6.73 | — | — | 8.78 | −23.3% |
| Net margin (%) | 29.6 | — | 30.5 |
Consolidated
- Filed with BSE
- 27 May 2019, 17:39 IST
- Board meeting
- 27 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 May 2019, 17:39 IST
- Board meeting
- 27 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE